GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (LTS:0A8U) » Definitions » EV-to-FCF

Synlogic (LTS:0A8U) EV-to-FCF : 0.14 (As of Mar. 13, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Synlogic EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Synlogic's Enterprise Value is $-4.36 Mil. Synlogic's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-31.67 Mil. Therefore, Synlogic's EV-to-FCF for today is 0.14.

The historical rank and industry rank for Synlogic's EV-to-FCF or its related term are showing as below:

LTS:0A8U' s EV-to-FCF Range Over the Past 10 Years
Min: -4.67   Med: -0.06   Max: 0.87
Current: 0.14

During the past 13 years, the highest EV-to-FCF of Synlogic was 0.87. The lowest was -4.67. And the median was -0.06.

LTS:0A8U's EV-to-FCF is ranked better than
92% of 425 companies
in the Biotechnology industry
Industry Median: 3.51 vs LTS:0A8U: 0.14

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-13), Synlogic's stock price is $1.248. Synlogic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.510. Therefore, Synlogic's PE Ratio (TTM) for today is At Loss.


Synlogic EV-to-FCF Historical Data

The historical data trend for Synlogic's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic EV-to-FCF Chart

Synlogic Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -1.15 0.11 -0.09 0.08

Synlogic Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.06 0.05 0.05 0.08

Competitive Comparison of Synlogic's EV-to-FCF

For the Biotechnology subindustry, Synlogic's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Synlogic's EV-to-FCF falls into.



Synlogic EV-to-FCF Calculation

Synlogic's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-4.357/-31.672
=0.14

Synlogic's current Enterprise Value is $-4.36 Mil.
Synlogic's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synlogic  (LTS:0A8U) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Synlogic's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.248/-2.510
=At Loss

Synlogic's share price for today is $1.248.
Synlogic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.510.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Synlogic EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Synlogic's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic Business Description

Traded in Other Exchanges
Address
301 Binney Street, Suite 402, Cambridge, MA, USA, 02142
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Synlogic Headlines

No Headlines